A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia

O'Connor A B, Noyes K, Holloway R G

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
17661955

DOI
10.1111/j.1532-5415.2007.01246.x

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Amines /economics /therapeutic use; Analgesics /economics /therapeutic use; Antidepressive Agents, Tricyclic /economics /therapeutic use; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids /economics /therapeutic use; Desipramine /economics /therapeutic use; Humans; Middle Aged; Neuralgia, Postherpetic /drug therapy /economics; Pregabalin; Randomized Controlled Trials as Topic;Severity of Illness Index; gamma-Aminobutyric Acid /analogs & derivatives /economics /therapeutic use

AccessionNumber
22007001686

Date bibliographic record published
06/09/2007